For more than 60 years, Ipca has been partnering healthcare globally in over 110 countries and in markets as diverse as Africa, Asia, Australia, Europe and the US.
Ipca is a fully-integrated Indian pharmaceutical company manufacturing over 350 formulations and 80 APIs for various therapeutic segments.
They are one of the world's largest manufacturers and suppliers of over a dozen APIs. These are produced right from the basic stage at manufacturing facilities endorsed by the world's most discerning drug regulatory authorities like US-FDA, UK-MHRA, EDQM-Europe, WHO-Geneva and many more.
Ipca is a therapy leader in India for anti-malarials with a market-share of over 34 per cent with a fast expanding presence in the international market as well. They have leading brands in 5 therapeutic areas, with 4 of our branded formulations being ranked among the Top-300 Indian brands by ORG-IMS.
Ipca Laboratories Ltd: Fully-integrated Indian pharmaceutical company
|2013||Ipca featured on the 8th position in the list of 'India's Most Admired Companies', in a survey carried out by Fortune India|
|2006||Ipca launches fixed dose ACT combination for treatment of malaria|
|1996||Ipca commissioned new API R&D centre at Mumbai|
|1986||Ipca first API Plant for manufacturing of chloroquine phosphate, set up at Ratlam|
|1976||Ipca started marketing of sugarcoated chloroquine tablets, first time in India|